OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E. Sands, Geert R. D’Haens, David B. Clemow, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 12, pp. 2245-2258
Open Access | Times Cited: 14
Bruce E. Sands, Geert R. D’Haens, David B. Clemow, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 12, pp. 2245-2258
Open Access | Times Cited: 14
Showing 14 citing articles:
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 9
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 9
Drug Development in Inflammatory Bowel Diseases: What Is Next?
Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 190-190
Open Access
Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 190-190
Open Access
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics
Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential
María José Mansilla, María Jesús Rodríguez‐Sojo, Andreea Roxana Lista, et al.
Antioxidants (2025) Vol. 14, Iss. 3, pp. 321-321
Open Access
María José Mansilla, María Jesús Rodríguez‐Sojo, Andreea Roxana Lista, et al.
Antioxidants (2025) Vol. 14, Iss. 3, pp. 321-321
Open Access
IL23p19 therapies for moderately-to-severely active ulcerative colitis
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis
Lushen Pillay, Sreedhar Subramanian
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 11, pp. 2238-2239
Closed Access | Times Cited: 1
Lushen Pillay, Sreedhar Subramanian
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 11, pp. 2238-2239
Closed Access | Times Cited: 1
Update CED: Sonografische Diagnostik und neue medikamentöse Therapien
Michelle A. Klose, Klaus Herrlinger, Eduard F. Stange
Gastro-News (2024) Vol. 11, Iss. 3, pp. 24-33
Closed Access
Michelle A. Klose, Klaus Herrlinger, Eduard F. Stange
Gastro-News (2024) Vol. 11, Iss. 3, pp. 24-33
Closed Access
Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
Junyu Xu, Ran Xie, Yongjia Ji, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 10, pp. 1143-1150
Closed Access
Junyu Xu, Ran Xie, Yongjia Ji, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 10, pp. 1143-1150
Closed Access
New treatments in inflammatory bowel disease � A thrilling time ahead
Fernando Gomollón
Revista Española de Enfermedades Digestivas (2024) Vol. 116
Open Access
Fernando Gomollón
Revista Española de Enfermedades Digestivas (2024) Vol. 116
Open Access
An evaluation of mirikizumab for the treatment of ulcerative colitis
Christopher J. White, Peter M. Irving
Expert Opinion on Biological Therapy (2024)
Closed Access
Christopher J. White, Peter M. Irving
Expert Opinion on Biological Therapy (2024)
Closed Access
Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
Simon Fung, Hannah A. Blair
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 11, pp. 433-443
Closed Access
Simon Fung, Hannah A. Blair
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 11, pp. 433-443
Closed Access
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study
Sumaiah J. Alarfaj, Mostafa M. Bahaa, Thanaa A. El‐Masry, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 5239-5253
Open Access
Sumaiah J. Alarfaj, Mostafa M. Bahaa, Thanaa A. El‐Masry, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 5239-5253
Open Access
Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins
Seung Min Hong, Won Moon
Korean Journal of Gastroenterology (2024) Vol. 84, Iss. 2, pp. 65-81
Open Access
Seung Min Hong, Won Moon
Korean Journal of Gastroenterology (2024) Vol. 84, Iss. 2, pp. 65-81
Open Access
Update CED: Sonografische Diagnostik und neue medikamentöse Therapien
Michelle A. Klose, Klaus Herrlinger, Eduard F. Stange
CME (2024) Vol. 21, Iss. 12, pp. 63-74
Closed Access
Michelle A. Klose, Klaus Herrlinger, Eduard F. Stange
CME (2024) Vol. 21, Iss. 12, pp. 63-74
Closed Access
